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Abstract 26 
Introduction Obesity is a well-established risk factor for developing type 2 diabetes mellitus 27 
(T2DM). Evidence suggests that sarcopenia, the age-related decline in muscle mass and 28 
strength, may exacerbate diabetes risk in obese individuals. The aim of this study was to 29 
determine the combined effect of obesity and low muscle strength, dynapenia, on the risk of 30 
incident T2DM in older adults. 31 
Methods Participants were 5953 (1670 obese) men and women from the English Longitudinal 32 
Study of Ageing without known T2DM at baseline and for whom handgrip strength, 33 
biochemical and other clinical data were collected. A diagnosis of T2DM was recorded from 34 
self-reported physician diagnosis over 6 years.  35 
Results For each unit increase in grip strength there was a reduction in diabetes risk (age and 36 
sex, BMI adjusted HR; 0.98; 95% CI 0.96-0.99). The risk of T2DM was elevated in all obese 37 
participants, but greatest in those with low handgrip strength (HR=4.93, 95% CI, 2.85, 8.53) 38 
compared to non-obese individuals with high handgrip strength. 11 % of the sample met the 39 
threshold for weakness (handgrip strength; men <26 kg; women <16kg) that was associated 40 
with elevated T2DM risk in obese (HR=3.57, 95% CI, 2.04, 6.24) but not in non-obese (HR= 41 
0.86, 95% CI, 0.44, 1.68) compared with normal/non-obese participants. 42 
Conclusion Dynapenic obesity, determined by high body mass index and low handgrip 43 
strength, is associated with increased risk of incident T2DM in older people. 44 
 45 
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Introduction  48 
Sarcopenia describes a syndrome characterised by a progressive, age-related loss of skeletal 49 
muscle mass causally related to low muscle strength and impaired physical performance with 50 
recent evidence based, clinically relevant diagnostic criteria proposedski [1]. Sarcopenia 51 
confers an increased risk of physical disability [2], and death [3]. Reflecting the observations 52 
that with ageing the decline in muscle strength exceeds that of muscle mass, a distinct term 53 
dynapenia has been proposed to describe the age-related loss of muscle strength[4]. 54 
Given that skeletal muscle constitutes the primary site for whole-body insulin-mediated 55 
glucose disposal[5], the association between low muscle mass and dysglycemia, 56 
independently of obesity, is perhaps unsurprising [6, 7]; there is also a clear association of 57 
sarcopenia with frank insulin resistance [8]. Furthermore, several cross-sectional studies have 58 
shown an association between handgrip strength, and features of the metabolic syndrome [6, 59 
8]. These data implicate sarcopenia and dynapenia in the pathophysiology of insulin 60 
resistance, the metabolic syndrome and type 2 diabetes (T2DM) with advancing age. 61 
Sarcopenic obesity, a co-occurrence of sarcopenia and obesity, is an emerging clinical entity 62 
in which these two conditions act in negative synergism in the pathophysiology of both 63 
metabolic and functional impairments. The prevalence of sarcopenic obesity depends on the 64 
definitions used, and differs considerably when sarcopenia is defined using handgrip strength 65 
[9, 10] or muscle mass [11-13]; Batsis et al. found that the prevalence of sarcopenic obesity 66 
in older adults varied enormously depending on the characteristics of the population and the 67 
definition applied [14].  68 
In sarcopenic obesity the metabolic syndrome is more prevalent than in either obesity or 69 
sarcopenia alone [15]. There is also cross-sectional evidence to suggest that sarcopenia may 70 
exacerbate obesity-associated insulin resistance, a risk factor for T2DM [13] and that 71 
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sarcopenic obesity is associated with poorer functional ability than either sarcopenia or 72 
obesity alone [16, 17]. However, to our knowledge no prospective evidence is available to 73 
determine whether sarcopenia and/or dynapenia has a synergistic effect with obesity on 74 
T2DM risk, that is, whether sarcopenic/dynapenic obesity is related to a greater risk of T2DM 75 
than non-sarcopenic/dynapenic obesity.  76 
Accordingly, the aim of this study was to utilise longitudinal population data to determine the 77 
association between low muscle strength, dynapenia, and risk of incident T2DM in lean and 78 
obese non-diabetic older individuals. 79 
 80 
Research Design and Methods 81 
Study sample and procedures 82 
The English Longitudinal Study of Ageing (ELSA) is an ongoing cohort study of a nationally 83 
representative sample of the English population born on or before 29 February 1952 living in 84 
private households. The ELSA data and documentation are publicly available and can be 85 
downloaded from the UK Data Service [18]. The sample was drawn using multi-stage 86 
stratified probability sampling with postcode sectors selected at the first stage and household 87 
addresses selected at the second stage. Participants gave full, informed written consent to 88 
participate in the study and ethical approval was obtained from the London multi-centre 89 
Research Ethics Committee. Data from participants who had a body mass index (BMI) <18.5 90 
kg/m2 were not included in the analysis as underweight is a risk factor for mortality and these 91 
participants may have contaminated the ‘normal weight’ category. There were too few 92 
underweight participants (n= 48) to be treated as a separate group. 93 
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The flow of participants is shown in Figure 1. For the purposes of the present analyses, data 94 
collected in 2004/05 (wave 2) were used as the baseline, as this was the first occasion on 95 
which clinical information was gathered (n=10,274). From this cohort, 441 were excluded at 96 
baseline with a known diagnosis of diabetes. Follow-up was then at two-yearly intervals: 97 
2006/7, 2008/9 and 2010/11. The final analytic sample consisted of 5953 individuals (1670 98 
obese and 4283 non-obese), reflecting 57.9% of the original baseline sample.  99 
Grip strength and anthropometric data collection 100 
Handgrip strength (kg) of the dominant hand was assessed using a hand-held dynamometer, 101 
using the average of three measurements[19]. Nurses collected anthropometric data (weight, 102 
height, waist circumference). Participants’ body weight was measured using Tanita electronic 103 
scales without shoes and in light clothing, and height was measured using a Stadiometer with 104 
the Frankfurt plane in the horizontal position; body mass index (BMI) was calculated using 105 
the standard formula [weight (kg)/height (m) squared]. Waist circumference (cm) was 106 
recorded twice mid-way between the iliac crest and lower rib using measuring tape: an 107 
average of the first two measurements was used provided these differed by no more than 108 
3cm; otherwise a third reading was taken and the two closest results averaged. 109 
Measurement of clinical characteristics 110 
Demographic and health-related questions included age, sex, cigarette smoking (current, 111 
previous, or non-smoker), the frequency of participation in vigorous, moderate, and light 112 
physical activities (more than once per week, once per week, one to three times per month, 113 
hardly ever), frequency of alcohol intake (daily, 5-6/week, 3-4/week, 1-2/week, 1-2/month, 114 
once every couple of months, 1-2/year or never). Depressive symptoms were assessed using 115 
the 8-item Centre of Epidemiological Studies Depression (CES-D) scale. Prevalent 116 
cardiovascular disease (including angina, heart disease, heart failure, heart murmur, 117 
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arrhythmia, stroke) was assessed via self-reported physician diagnosis. Systolic and diastolic 118 
blood pressure was measured with an Omron HEM-907 blood pressure monitor three times in 119 
the sitting position after 5 min rest between each reading: the initial reading was discarded 120 
and the second and third measurements averaged.  121 
Blood samples were obtained from a sub-sample of participants who consented and were 122 
eligible and able to give blood; this excluded men and women with clotting and bleeding 123 
disorders, or taking anti-coagulant medication. Blood samples were taken and analyzed for C-124 
reactive protein (CRP), fibrinogen, total and high-density lipoprotein (HDL) cholesterol, 125 
triglycerides, and glycated haemoglobin (HbA1c). Blood analysis was carried out at the 126 
Royal Victoria Infirmary (Newcastle-upon-Tyne, UK). Detailed information on the 127 
technicalities of the blood analysis, the internal quality control, and the external quality 128 
assessment for the laboratory have been described elsewhere [20].  129 
Incident type 2 diabetes 130 
Diabetes was recorded from self-reported physician diagnosis, which has been previously 131 
validated in ELSA through objective HbA1c measures[21]. Participants with known diabetes 132 
at baseline were excluded. Incident cases of diabetes were recorded at follow-up in 2006/7, 133 
2008/9, and 2010/11; mean follow-up period 5.9 years. Participants that died, moved away 134 
from the UK, or institutionalised over follow up were censored at the date of study exit and 135 
retained in the analysis. 136 
Statistical analyses 137 
Characteristics of the study population at baseline were described as means (continuous 138 
variables) with standard deviations or the median with interquartile range (skewed variables), 139 
and percentages (categorical variables). ANOVA and chi-squared tests were used to test 140 
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differences between grip strength groups. C-reactive protein was log-transformed prior to 141 
performing these tests. We used Cox proportional hazards models to compute hazard ratios 142 
(HR) with 95% confidence intervals (CI) for the association of handgrip strength with 143 
incident diabetes. The proportional hazards assumption was examined by comparing the 144 
cumulative hazard plots grouped on the various exposure variables, and no appreciable 145 
violations were noted. The models were initially run using grip strength as a continuous 146 
variable and also fitting a grip strength ˣ BMI interaction term. A significant (p<0.001) 147 
interaction term between hand grip and BMI prompted us to perform these analyses stratified 148 
by BMI category (Obesity was defined as BMI ≥ 30 kg/m2 and ‘non-obese’ defined as BMI < 149 
30 kg/m²). We also conducted supplementary analysis according to presence of central 150 
obesity defined as waist circumference >102cm in men and >88cm in women. Due to the 151 
strong associations between sex and grip strength we further categorized the data into sex-152 
specific tertiles of handgrip strength, although no mediating effects of sex were observed 153 
after entering an interaction term in relation to diabetes outcome (p=0.21). Age was the time 154 
scale, and for participants with no record of an event, the data were censored at wave 5 155 
(maximum 6 years follow-up). In multivariate models we adjusted for several covariates in a 156 
step-wise fashion: Model 1 contained age and sex; Model 2 contained additional behavioural 157 
and health covariates, including smoking, alcohol, physical activity, depressive symptoms 158 
and prevalent CVD. All analyses were conducted using SPSS version 21 (IBM SPSS, 159 
Armonk, NY, USA). 160 
Results  161 
 162 
5953 individuals (1670 obese and 4283 non-obese; 98% white British), who were free of 163 
T2DM at baseline, completed follow-up. Of these 124 obese and 92 non-obese individuals 164 
were diagnosed with T2DM over the follow-up period.  165 
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There were few differences in those excluded compared to those included. For example, the 166 
samples were comparable in sex distribution (% men; 42.6% vs. 45%) and age (65 vs. 63y). 167 
The samples differed in physical activity behaviour and mental health, with those excluded 168 
reporting higher inactivity (33% vs. 19%), and depressive symptoms (21% vs. 13%). 169 
In men, the range of handgrip strength was 4–35.3, 35.4–44.2, >44.2 kg for bottom, 170 
intermediate and top tertiles. The corresponding ranges in women were 4–19.6, 19.7–24.9, 171 
>24.9 kg, respectively. Table 1 shows that obese individuals in the lowest sex-specific tertile 172 
of handgrip strength were significantly older than those with either intermediate or upper 173 
tertile of handgrip strength (p<0.001), and were less likely to engage in any moderate or 174 
vigorous physical activity (34.4% inactive; p<0.001). Despite similar smoking patterns across 175 
the three groups, the lowest handgrip strength group had a significantly higher prevalence of 176 
cardiovascular disease (p<0.001).  177 
Obese participants were well matched in terms of BMI (~33-34 kg/m2) and waist 178 
circumference, across tertiles of handgrip strength (table 2). At baseline, the low handgrip 179 
strength group had significantly higher percentages of glycated haemoglobin  compared to 180 
those with intermediate or high handgrip strength. Furthermore, the low handgrip strength 181 
group had higher circulating concentrations of CRP and fibrinogen  compared to those with 182 
intermediate strength or low strength (p<0.001 and 0.009 respectively).  183 
We assessed the linearity of the association between handgrip strength and incident diabetes 184 
in all participants by entering a squared term into the models although no deviation was 185 
noted. We observed that for each unit increase in grip strength there is a reduction in diabetes 186 
risk (age and sex, BMI adjusted HR; 0.98; 95% CI 0.96-0.99).   187 
The results from the analysis of T2DM risk in non-obese and obese individuals according to 188 
handgrip strength are shown in Table 3. T2DM risk did not significantly differ between the 189 
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three tertiles of handgrip strength for non-obese participants after multivariate adjustment. 190 
The risk of T2DM was elevated in all obese participants, particularly so in those with low 191 
handgrip strength (HR=4.93, 95% CI, 2.85, 8.53) compared to non-obese individuals with 192 
high handgrip strength after multivariate adjustment.  193 
Sensitivity analyses 194 
We categorised participants using sex-specific handgrip cut offs (men <26 kg; women 195 
<16kg) for those at risk for weakness [1]. 11% of the sample met these thresholds for 196 
weakness although the pattern of results largely replicated the original results showing the 197 
same finding that sarcopenic obese were at the highest risk of incident diabetes (Table 4). In 198 
addition, we used these handgrip cut offs in combination with waist circumference as a 199 
measure of central obesity (defined as waist circumference >102cm in men and >88cm in 200 
women). When using central obesity rather than body mass index the influence of sarcopenia 201 
was less pronounced (Table 5; n= 6134).  202 
Discussion  203 
We found that obese older adults with the lowest tertile of muscle (handgrip) strength had a 204 
greater risk of developing T2DM over six years of follow-up compared with individuals of 205 
similar age and BMI with greater handgrip strength. Although adjustment for age, sex, 206 
physical activity, smoking, alcohol, depressive symptoms and prevalent cardiovascular 207 
disease partly attenuated this risk, the association persisted. In contrast, low handgrip strength 208 
did not confer a higher risk of incident T2DM in non-obese individuals. This suggests that 209 
individuals with dynapenic obesity represent a sub-group of obesity with an amplified risk of 210 
T2DM beyond that for individuals with non-dynapenic obesity.  211 
We obtained evidence of a dose-response association, as there was a clear incremental 212 
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increase in both incident risk of T2DM and in plasma HbA1c concentration progressively 213 
from the upper to lower handgrip strength tertile. There was also a linear reduction in incident 214 
diabetes risk for each unit increase in grip strength. Analysis of HbA1c with incident diabetes 215 
risk was not performed due to missing biochemistry data.  216 
However, we did not observe significant differences in waist circumference, blood pressure, 217 
lipid profile or fasting blood glucose, although low handgrip strength seemed to be 218 
accompanied by chronic low-grade inflammation, with significantly higher serum 219 
concentrations of highly sensitive CRP (hsCRP) and fibrinogen and a higher prevalence of 220 
cardiovascular disease. This association has been noted in several other epidemiological 221 
studies [22, 23] and highlights a common pathophysiological defect.  222 
The clinical relevance of measurements of both muscle mass and muscle strength is reflected 223 
in the revised definition of sarcopenia from the Foundation for the National Institutes of 224 
Health (FNIH) Sarcopenia Project to incorporate both anatomical and functional components 225 
[1]. These newer guidelines are more clinically meaningful as they denote the functional 226 
consequences and thus relate more closely to clinical outcomes.  Goodpaster et al. examining 227 
longitudinal changes in muscle mass and strength in older adults in the Health, Ageing and 228 
Body Composition Study demonstrated (annualised) rates of leg strength decline (~3%/year) 229 
approximately three times greater than the rates of leg lean mass (~1%/year) [24]. These 230 
findings clearly implicate factors other than muscle mass in determining muscle strength and 231 
these updated guidelines reflect, and take account of, this important anatomical and 232 
functional discrepancy. Thus, low grip strength is likely similarly explained by factors other 233 
than low muscle mass. Indeed, many individuals with weakness may not have low muscle 234 
mass. This had led to suggestions of a distinct term, dynapenia [25]. For practical reasons, 235 
longitudinal measurements collected in this cohort did not extend to quantification of skeletal 236 
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muscle mass and we therefore must rely on measurements of muscle strength alone for the 237 
current study.  238 
We chose to analyse hand grip as a continuous variable using sex-specific tertiles. In 239 
subsequent analysis we used the suggested cut points for weakness according to the FNIH 240 
criteria as previously defined (ref). However, only 11.4% of the sample met the threshold for 241 
weakness based on their handgrip (this reflects a higher prevalence of sarcopenia as a 242 
disabling condition than that observed in the FNIH project of 0.4-4% of elderly women and 243 
men) (ref) thus limiting our statistical power. Indeed, one of the limitations of using a cut 244 
point, such as the FNIH, is loss of power and information. Thus our approach of using tertiles 245 
enabled us to create equal groups across our specific sample, which helped to retain 246 
information and better examine linear trends. Interestingly, whichever thresholds for 247 
weakness were applied the association between weakness and incident T2DM remained the 248 
same for the obese participants.  249 
In many T2DM patients with advancing age, severe obesity and comorbidities including 250 
cardiovascular disease and osteoarthritis aerobic exercise is not feasible. In contrast, 251 
resistance training provides an effective exercise alternative by increasing muscle mass and 252 
strength (and thus counteracting age- and disease-related skeletal muscle loss and muscle 253 
weakness), in visceral fat deposition and improvements in insulin sensitivity and glycemic 254 
control [26, 27]. Thus our findings are biologically plausible. Skeletal muscle represents a 255 
major organ for glucose homeostasis, responsible for up to 75% of post-prandial (i.e. insulin-256 
stimulated) glucose uptake [5]. Low muscle mass might therefore be expected to impair 257 
glucose homeostasis. There is epidemiological evidence in obese, older individuals to link 258 
sarcopenia with the metabolic syndrome and with T2DM [28], although it is not possible to 259 
infer temporality between these conditions from cross-sectional data. Longitudinal studies 260 
have shown an accelerated decline in muscle mass over several years in patients already 261 
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diagnosed with T2DM, compared with age- and BMI-matched healthy controls [29].  262 
Although those with low handgrip strength were less likely to be physically active, statistical 263 
adjustment for physical activity did not alter the predominant relationship, suggesting that the 264 
increased risk of T2DM in weaker individuals does not merely reflect more sedentary 265 
behaviour. Evidence from human and transgenic animal models that interventions influencing 266 
skeletal muscle growth and/or metabolism are protective against metabolic diseases may 267 
provide some further mechanistic insight: preservation of oxidative capacities in aged 268 
muscles prevents muscle loss, reduces intramyocellular lipid accumulation and protects 269 
against metabolic diseases [30]; up-regulation of PGC1-α, a master regulator of 270 
mitochondrial metabolism, protects against age-related muscle loss and improves insulin 271 
resistance [31]; and importantly, in patients with T2DM resistance exercise, a potent anabolic 272 
stimulus for skeletal muscle, significantly improves glycaemic control [32]. 273 
We acknowledge some limitations of this study. The nature of large-scale, population-based 274 
longitudinal studies makes sample attrition and incomplete data collection inevitable. 275 
Biochemical measurements were only available for 4186 from a total of 5953 participants, 276 
and this may be a source of selection bias, with participants able to provide samples likely to 277 
be in better health. Although we saw that for each unit increase in grip strength there is a 278 
reduction in diabetes risk (HR 0.98; 95% CI 0.96-0.99), the missing biochemical data made 279 
analysis of the relationship of grip strength with HbA1c impractical.  280 
A further limitation is the use of questionnaires to ascertain diagnosis of T2DM, although 281 
self-reported physician-diagnosed diabetes has been well validated with HbA1c in the ELSA 282 
sample. Since self-reported physician diagnosis of diabetes cannot account for undetected 283 
cases, our results might be biased towards the obese sample who may be more likely to be 284 
diagnosed because of more frequent contact with health services to treat other risk factors. 285 
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Furthermore this potentially could lead to reverse causation with undiagnosed T2DM at 286 
baseline being associated with low grip strength. Formal assessment using physical activity 287 
monitors and biannual glucose tolerance tests might have afforded further mechanistic 288 
insight, particularly with respect to the domains of physical activity and degrees of insulin 289 
resistance. Our sample was also predominantly white-European, and results may therefore 290 
not directly apply to older adults of other ethnic groups, such as those of black ethnicities. 291 
In conclusion, the risk of developing T2DM was significantly increased in older obese adults 292 
with low muscle strength, a finding that cannot be fully explained by levels of physical 293 
activity or other risk factors. Our findings suggest that dynapenic obesity in older adults 294 
represents a form of obesity which is related to particularly high risk of T2DM. Further 295 
research is needed to examine whether strategies to increase muscle strength would reduce 296 
diabetes risk in obese older adults.  297 
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Figure 1 Flow chart describing the selection of participants for the present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2004/05 (baseline) 
N=10,274 
Diabetes at baseline = 441 
 
Missing baseline data = 3880 
2010/11 (follow-up)  
N= 5,953 (4186 with 
bloods) 
(1670 obese/4283 non-
obese) 
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Table 1 Demographic characteristics of the sample in relation to grip strength (n=5953) 
Variables Sex-specific handgrip strength tertileb 
Non-obese (n=4283) 
Sex-specific handgrip strength tertileb 
Obese (n=1670) 
High 
(n=1391) 
Intermediate  
(n=1502) 
Low 
(n=1390)  
p value High 
(n=603) 
Intermediate  
(n=571) 
Low 
(n=496)  
 
Age (y)a 58.3±6.1 63.0±8.3 69.6±9.8 <0.05 58.2±6.3 62.8±8.0 67.6±8.9 <0.05 
Men (%) 38.0 49.8  50.9 <0.05 39.5 45.5  39.7 0.14 
Smoking 
Current 
 
17.8 
 
16.3 
 
16.1 
 
0.44 
 
14.2 
 
15.0 
 
11.3 
 
<0.05 
Alcohol intake (%) 
Daily 
At least 1/wk (but not daily) 
Rarely 
Never 
 
28.8 
42.4 
23.4 
5.4 
 
27.2 
41.3 
24.2 
7.3 
 
24.3 
35.2 
27.5 
13.0 
<0.05  
19.7 
41.5 
29.7 
9.1 
 
19.4 
34.2 
35.2 
11.2 
 
12.9 
35.5 
35.1 
16.5 
<0.05 
Physical activity (%) 
Inactive 
 
8.8 
 
13.3 
 
27.0 
 
<0.05 
 
16.6 
 
23.8 
 
38.1 
 
<0.05 
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Moderate (at least 1/week) 
Vigorous (at least 1/week) 
48.5 
42.8 
51.4 
35.3 
52.2 
20.8 
55.6 
27.9 
51.5 
24.7 
43.8 
18.1 
Depressive symptoms (%) 9.3 10.9 16.3 <0.05 12.4 13.3 17.9 <0.05 
Prevalent CVD (%) 11.3 12.9 15.8 <0.05 10.8 14.5 15.9 <0.05 
aData presented as mean± SD 
b In men, the range of handgrip strength was 4 – 35.3, 35.4 – 44.2, >44.2 kg for bottom, intermediate and top tertile. The corresponding ranges in 
women were 4 – 19.6, 19.7 – 24.9, >24.9 kg , respectively. 
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Table 2 Sarcopenic obesity and biomarkers in the 4,186 individuals in whom biochemical data were available.  
Variable  Sex-specific handgrip strength tertilea   
Non-obese 
Sex-specific handgrip strength tertilea  
Obese 
High  
(n=1082) 
Intermediate  
(n=1085) 
Low 
(n=908) 
p value High 
(424) 
Intermediate 
(n=380) 
Low 
(n=307) 
p value 
         
Body mass index (kg/m2) 25.8±2.5 25.7±2.6 25.2±2.7 <0.001 33.9±3.8 33.4±3.6 33.6±3.3 0.38 
Waist circumference (cm) 89.0±11.6 90.4±12.2 89.6±13.6 0.005 105.3±16.0 105.6±16.0 105.5±13.1 0.78 
Systolic blood pressure (mmHg) 131.2±16.9 133.5±18.9 134.6±19.1 <0.001 138.1±17.1 138.6±18.2 139.5±17.7 0.61 
Glycated haemoglobin (%) 
Glycated haemoglobin (mmol/mol) 
5.4±0.5 
35±5 
5.5±0.5 
36±5 
5.5±0.6  
37±6 
<0.001 5.6±0.6 
38±8 
5.6±0.5 
38±6 
5.8±0.8 
40±9 
 0.034 
Total cholesterol (mmol/l)  6.17±1.21 6.02±1.31 5.79±1.19 <0.001 6.16±1.21 5.90±1.31 5.81±1.19 <0.001 
HDL cholesterol (mmol/l)  1.62±0.33 1.58±0.33 1.55±0.32 <0.001 1.44±0.33 1.42±0.33 1.42±0.32 0.26 
Triglycerides (mmol/l) 1.64±1.33 1.64±1.12 1.63±1.23 0.80 2.08±1.33 2.03±1.12 2.02±1.23 0.58 
C-reactive protein (mg/l)b 1.3 (1.9) 1.6 (2.4) 1.9 (2.8)  <0.001 3.3 (3.7) 3.0 (4.2) 3.8 (5.4)  <0.001 
Fibrinogen (g/l) 2.94±0.67 3.09±0.70 3.23±0.67 <0.001 3.24±0.67 3.28±0.70 3.39±0.67 <0.001 
Data presented as mean± SD unless otherwise stated;  
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aIn men, the range of handgrip strength was 4 – 35.3, 35.4 – 44.2, >44.2 kg for bottom, intermediate and top tertile. The corresponding ranges in 
women were 4 – 19.6, 19.7 – 24.9, >24.9 kg  , respectively. 
bmedian (interquartile range).  
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Table 3 Associations between handgrip strength and risk of incident type 2 diabetes among obese and non-obese participants free of physician 
diagnosed diabetes at baseline (n=5,953). 
 
Sex-specific handgrip  
strength tertile 
Cases/n Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Non-obese participants    
High 21/1391 1.00 (reference) 1.00 (reference) 
Intermediate  36/1502 1.54 (0.90, 2.63) 1.49 (0.86, 2.53) 
Low 35/1390 1.72 (0.98, 3.02) 1.51 (0.86, 2.66) 
Obese participants    
High 33/603 3.47 (2.03, 5.96) 3.25 (1.89, 5.60) 
Intermediate  49/571 5.68 (3.42, 9.45) 4.85 (2.90, 8.11) 
Low 42/496 5.97 (3.49, 10.23) 4.93 (2.85, 8.53) 
 
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, physical activity, smoking, alcohol, depressive symptoms, prevalent 
cardiovascular disease (angina, heart disease, heart failure, heart murmur, arrhythmia, stroke) 
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Table 4 Associations between handgrip strength using a binary cut off point with weakness defined as handgrip < 26kg in men and < 16 kg in 
women and risk of incident type 2 diabetes among obese and non-obese participants free of physician diagnosed diabetes at baseline (n=5953). 
 
Sex-specific handgrip  
strength using binary cut * 
Cases/n Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Non-obese participants    
Normal 82/3789 1.00 (reference) 1.00 (reference) 
Weak  10/494 0.97 (0.49, 1.90) 0.86 (0.44, 1.68) 
Obese participants    
Normal 108/1484 3.43 (2.57, 4.57) 3.13 (2.33, 4.18) 
Weak   16/186 4.27 (2.47, 7.37) 3.57 (2.04, 6.24) 
*Weakness defined as handgrip < 26kg in men and < 16 kg in women. 
Model 1: adjusted for age and sex.  
Model 2: adjusted for age, sex, physical activity, smoking, alcohol, depressive symptoms, and prevalent cardiovascular disease (angina, heart disease, heart 
failure, heart murmur, arrhythmia, stroke) 
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Table 5 Associations between handgrip strength and risk of incident type 2 diabetes among centrally obese and non-obese participants free of 
physician diagnosed diabetes at baseline (n=6134). 
 
Sex-specific handgrip  
strength using binary cut * 
Cases/n Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Non-obese participants    
Normal 37/2656 1.00 (reference) 1.00 (reference) 
Weak  7/388 1.51 (0.66, 3.43) 1.32 (0.58, 3.00) 
Obese participants†    
Normal 158/2742 4.39 (3.07, 6.28) 4.09 (2.85, 5.87) 
Weak   19/348 4.82 (2.72, 8.55) 3.99 (2.23, 7.13) 
*Weakness defined as handgrip < 26kg in men and < 16 kg in women. 
†Central obesity defined as waist circumference >102cm in men and >88cm in women 
 
Model 1: adjusted for age and sex.  
Model 2: adjusted for age, sex, physical activity, smoking, alcohol, depressive symptoms, and prevalent cardiovascular disease (angina, heart disease, heart 
failure, heart murmur, arrhythmia, stroke) 
 
 
